BenevolentAI achieves second major collaboration milestone with novel idiopathic pulmonary fibrosis target selected for AstraZeneca's portfolio
London (ots/PRNewswire) - - Novel target for idiopathic pulmonary fibrosis was discovered using BenevolentAI's AI-drug discovery platform and experimentally validated by AstraZeneca - Announcement represents the second collaboration milestone following the addition of a novel chronic kidney disease target to ...
mehr